痛风患者高尿酸血症之治疗Therapyforhyperuricemiaingout

1、痛风患者高尿酸血症之治疗Therapyforhyperuricemiaingout主題選取的考量常見的疾病高盛行率醫療花費增加臨床治療標準不一國際已有治療指引主題選取的考量常見的疾病高盛行率資料來源：PubMedKeyword: Hyperuricemia in Taiwan16篇 since 1968 to 2004主題選取的考量常見的疾病高盛行率Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwa

2、n (1993-96). J Rheumatol. 2001 Jul;28(7):1640-6. Population: 2754 males and 2953 females aged 4 years and older The prevalence of hyperuricemia in aboriginal males and females：50 尿酸值 年齡男性 7.7 mg/dl 女性 6.6 mg/dl 19y/o261745y/o2223主題選取的考量常見的疾病高盛行率Lai SW, Tan CK, Ng KC. Epidemiology of hyperuricemia in

3、 the elderly. Yale J Biol Med. 2001 May-Jun;74(3):151-7. Time： 1998 MayPopulation：586 (66% Men & 34%Women) mean age was 73.1+/-5.3 years The proportions of hyperuricemia ： (p 416.5 micromol/l (7 mg/dl) in boys and 357 micromol/l (6 mg/dl) in girls Ninety of 224 girls (40.2%) and 56 of 190 boys (29.5

4、%) were hyperuricemic. 主題選取的考量常見的疾病高盛行率CHOU Chungtei 周昌德 Hyperuricemia and gout among Taiwan Aborigines and Taiwanese-prevalence and risk factors Chin Med J 2003;116(7):965-967 The prevalence of hyperuricemia and gout in Atayal Aborigines to be 41.4% and 11.7%, respectively. 27% to 45% of aboriginal

5、 boys and 13% to 41% of aboriginal girls had hyperuricemia. Kinmen：the prevalence of hyperuricemia in men was 25.8% (391/1515) through more than 6 years of follow-ups on 223 asymptomatic hyperuricemic patients, the 5-year cumulative incidence of onset of gout was 18.8% (42/223). The incidence increa

6、sed with three different baseline levels of uric acid, from 10.8% (7.0 uric acid8.0), to 27.7% (8.0uric acid 9.0), to 61.6% (uric acid9.0). 主題選取的考量國際已有治療指引資料庫：PubMedKeyword: Hyperuricemia guideline 8篇，since 1996 to 20031: Meyers OL, Cassim B, Mody GM. Hyperuricaemia and gout: clinical guideline 2003

7、. S Afr Med J. 2003 Dec;93(12 Pt 2):961-71. 2: Nakajima H, Matsuzawa Y. Introduction of the new guideline for the management of hyperuricemia and gout with special reference to its policy Nippon Rinsho. 2003 Jan;61 Suppl 1:442-9. 3: Tatsuno I, Saito Y. Hyperuricemia and atherosclerosis Nippon Rinsho

8、. 2003 Jan;61 Suppl 1:259-65. Review. 主題選取的考量國際已有治療指引4: Nakajima H. Definition and determination of serum uric acid level Nippon Rinsho. 2003 Jan;61 Suppl 1:154-7. 5: Nakajima H. Management of hyperuricemia in occupational health: with reference to guidelines for the management of hyperuricemia and

9、gout Sangyo Eiseigaku Zasshi. 2003 Jan;45(1):12-9. Review. Japanese.6: Gorter KJ, Romeijnders AC. The standard hyperuricemia from the Dutch Family Physician; reaction from rheumatology and general medicine Ned Tijdschr Geneeskd. 2002 May 4;146(18):872; author reply 872-3. Dutch. 7: Chalmers J. Role

10、of diuretics in the treatment of hypertension: from large controlled trials to international guidelines Arch Mal Coeur Vaiss. 1996 Sep;89 Spec No 4:39-43. Review. French. 8: Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and l

11、ung transplantation. Transplantation. 1996 Jun 15;61(11):1661-2. 目前製作guideline之目的台灣地區高尿酸血症的盛行率驚人，尤其施行成人健康體檢後，門診診療中常遇到病人詢問高尿酸血症該如何處理。而目前因無統一的guideline可供依循，治療標準不一，常造成醫師及患者的困擾。期待檢視文獻後，能提供有用的資訊，建立使用降尿酸藥物之臨床底線，以為臨床診療之準則。臨床問題1：無症狀之高尿酸血症需不需要治療？資料來源：PubMedKeyword: Asymtomatic hyperuricemia and treatment and

12、 review 23篇，since 1977 to 2003臨床問題1：無症狀之高尿酸血症需不需要治療？Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002 Aug;69(8):594, 597, 600-2 passim. Publication Types: ReviewTreatment of asymptomatic hyperuricemia is not necessary in most patients, un

13、less perhaps they have very high levels of uric acid or are otherwise at risk of complications, such as those with a personal or strong family history of gout, urolithiasis, or uric acid nephropathy.臨床問題1：無症狀之高尿酸血症需不需要治療？Uhlig T. Gout and hyperuricaemia-should both be treated? Tidsskr Nor Laegeforen

14、. 2003 Oct 23;123(20):2878-80 Publication Types: ReviewPatients with increased levels of uric acid will usually be treated with drugs if symptoms of acute arthritis or kidney stones occur. There is still no consensus on the treatment of individuals with asymptomatic hyperuricaemia.臨床問題1：無症狀之高尿酸血症需不需

15、要治療？Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999 Feb 15;59(4):925-34. Publication Types: Review Patients with asymptomatic hyperuricemia do not require treatment, but efforts should be made to lower their urate levels by encouraging them to make changes in diet or

16、 lifestyle. 臨床問題1：無症狀之高尿酸血症需不需要治療？Pollmann G, Kullich W, Klein G. Therapy of hyperuricemia and gout Wien Med Wochenschr. 1997;147(16):382-7 Publication Types: Review Dietary regimen are in the forefront in treatment of asymptomatic hyperuricemia. Uric acid lowering drugs can only be supported in rep

17、eated serum-measures from 9 mg/dl up. 臨床問題2：痛風患者高尿酸血症之治療Keyword: Hyperuricemia and Gout and treatment資料來源：PubMed Bandolier Google 臨床問題2：痛風患者高尿酸血症之治療Uhlig T. Gout and hyperuricaemia-should both be treated? Tidsskr Nor Laegeforen. 2003 Oct 23;123(20):2878-80 Publication Types: ReviewDrugs for the trea

18、tment of acute arthritis attacks include non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids systematically or injected into the joint, and colchicine. As prophylactic long-term treatment of recurring attacks, allopurinol, probenicide and colchicine are therapeutic alternatives. 臨床問題2：痛風

19、患者高尿酸血症之治療Pittman JR. et al Diagnosis and management of gout. Am Fam Physician 1999 Apr 1;59(7):1799-806, 1810 Treatment goals (of gout) include termination of the acute attack, prevention of recurrent attacks and prevention of complications associated with the deposition of urate crystals in tissue

20、s. Pharmacologic management remains the mainstay of treatment.Acute attacks may be terminated with the use of nonsteroidal anti-inflammatory agents, colchicine or intra-articular injections of corticosteroids. Probenecid, sulfinpyrazone and allopurinol can be used to prevent recurrent attacks. Obesi

21、ty, alcohol intake and certain foods and medications can contribute to hyperuricemia. These potentially exacerbating factors should be identified and modified臨床問題2：痛風患者高尿酸血症之治療Pollmann G, Kullich W, Klein G. Therapy of hyperuricemia and gout Wien Med Wochenschr. 1997;147(16):382-7 Publication Types:

22、 Review The therapy of an acute attack of gout primarily is done with non-steroidal antiinflammatory drugs, in rare cases with colchicine or corticoids. Gouty arthritis in intermission, independent of the extent of hyperuricemia, as well as chronic gout are indications for an uric acid lowering phar

23、macotherapy, usually for life. 臨床問題2：痛風患者高尿酸血症之治療Rott KT, Agudelo CA: Gout. JAMA. 2003;289(21):2857-60. A short, practical, up-to-date review article targeted at the non-rheumatologist clinician. Agudelo CA, Wise CM: Crystal-associated arthritis in the elderly. Rheum Dis Clin North Am. 2000;26(3):52

24、7-46. A comprehensive review by two of the leading authorities on gout and other crystal-induced arthropathies. Emmerson BT: The management of gout. N Engl J Med. 1996;334(7):445-51.A dated but insightful classic review article. PRODIGY Guidance - Gout. April 2002. A practical UK guideline that may

25、be particularly useful for US clinicians, especially until a standard evidence-based US clinical guideline is available.臨床問題2：痛風患者高尿酸血症之治療Bandolier：Allopurinol, oxipurinol, benzbromarone and probenecid for lowering uric acidHE Paulus et al. Prophylactic colchicine therapy of intercritical gout. A pl

26、acebo-controlled study of probenecid-treated patients. Arthritis and Rheumatism 1974 17: 609-614.HR Arntz et al. Serum uric acid lowering effect of allopurinol and benzbromarone in low dosage. Fortschr Med 1979 19: 1-3.GW Schepers et al. Benzbromarone therapy in hyperuricaemia: comparison with allop

27、urinol and probenecid. J Int Med Res 1981 9: 511-515.PW Bull & JT Scott. Intermittent control of hyperuricaemia in the treatment of gout. J Rheumatol 1989 16: 1246-1248.H Berg. Effectiveness and tolerance of long-term uricosuric treatment. Z Gestamte Inn Med 1990 45: 719-20.I Walter-Sack et al. Uric

28、 acid lowering effects of oxipurinol sodium in hyperuricaemic patients - therapeutic equivalence to allopurinol. J Rheumatol 1996 23: 498-501. ReferenceDesignIncluded patientsoutcomesResultsHE Paulus et al, 1974 Randomised, double blind comparison of probenecid 500 mg three times a day plus placebo

29、versus probenecid plus colchicine for up to six months 53 men with gout and serum uric acid above 7.5 mg/dLUric acidResults reported only for men with significant and sustained falls in uric acid (38/52), when mean reduction was to 6.3 mg/dL from about 8.8 mg/dL. Acute attacks 0.5/month with probene

30、cid alone, and 0.2/month with probenecid plus colchicine. Pretreatment attacks averaged 3-4/12 months. Table 1: Allopurinol, benzbromarone and probenecid in goutReferenceDesignIncluded patientsoutcomesResultsArntz et al, 1979 Random comparison of 100 mg allopurinol, 20 mg benzbromarone and the combi

31、nation in a crossover trial with four week treatment periods Twelve patients with hyperuricaemia and type IV hyperlipidaemia Uric acid Significant falls for all treatments, but more so for the combination. Table 1: Allopurinol, benzbromarone and probenecid in goutReferenceDesignIncluded patientsoutc

32、omesResultsSchepers, 1981 Non-random crossover of probenecid 1000 mg, allopurinol 300 mg daily, benzbromarone 100 mg daily in six patients. One week of treatment with two week wash out. Serum uric acid of 450 mol/L or more. Uric acid Claims benzbromarone superior to other two treatments Table 1: All

33、opurinol, benzbromarone and probenecid in goutReferenceDesignIncluded patientsoutcomesResultsBull & Scott, 1989 Random (last digit of hospital number) to continuous daily allopurinol 300 mg (10) or allopurinol 300 mg (10) for two months every year. Aim of continuous treatment was uric acid below 6 m

34、g/100 mL. Duration 2-4 years. At least three attacks of classical gouty arthritis with hyperuricaemia. Patients new to allopurinol. Acute attacks 20 attacks versus 26 attacks (continuous /intermittent) in first two years. No attacks per 166 patient months thereafter for continuous, versus 10/140 months for intermittent. Table 1: Allopurinol, benzbromarone and probenecid in goutReferenceDesignIncluded patientsoutcomesResultsBerg, 1990 Randomised comparison of 100 mg allopurinol plus 20 mg benzbromarone daily compa